2,3-Diphenyl-1,4-Naphthoquinone: A potential chemotherapeutic agent against trypanosoma cruzi

Journal of Parasitology

Volumn 95, Issue 2, 2009, Pages 461-466

  Ramos, Enrique I ^a   Garza, Kristine M ^a   Krauth Siegel, R L ^a,b   Bader, Julia ^a   Martinez, Luiz E ^a   Maldonado, Rosa A ^a  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHENYL 1,4 NAPHTHOQUINONE; ANTITRYPANOSOMAL AGENT; UNCLASSIFIED DRUG; 2,3-DIPHENYL-1,4-NAPHTHOQUINONE; DIHYDROLIPOAMIDE DEHYDROGENASE; ENZYME INHIBITOR; NAPHTHOQUINONE;

CHAGAS DISEASE; CHEMOTHERAPY; DRUG; INFECTIVITY; QUININE; TOXIC SUBSTANCE;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; ENZYME KINETICS; EPIMASTIGOTE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CELL; MAMMAL CELL; MOUSE; NONHUMAN; PARASITEMIA; TREATMENT DURATION; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE; ANIMAL; C3H MOUSE; CELL LINE; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; LD 50; PARASITOLOGY;

LATIN AMERICA;

ANIMALIA; MAMMALIA; MURINAE; TRYPANOSOMA CRUZI;

ANIMALS; CELL LINE; CHAGAS DISEASE; DIHYDROLIPOAMIDE DEHYDROGENASE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; LETHAL DOSE 50; MICE; MICE, INBRED C3H; NAPHTHOQUINONES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 67651091668     PISSN: 00223395     EISSN: None     Source Type: Journal    
DOI: 10.1645/GE-1686.1     Document Type: Article

References (36)

1. ANDRADE, A. L., C. M. MARTELLI, R. M. OLIVEIRA, S. A. SILVA, A. I. AIRES, L. M. SOUSSUMI, D. T. COVAS, L. S. SILVA, J. G. ANDRADE, L. R. TRAVASSOS, ET AL. 2004. Short report: Benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. American Journal of Tropical Medicine and Hygiene 71: 594-597.
2. ANDREWS, N. W., AND W. COLLI. 1982. Adhesion and interiorization of Trypanosoma cruzi in mammalian cells. Journal of Protozoology 29: 264-269.
3. BLUMENSTIEL, K., R. SCHONECK, V. YARDLEY, S. L. CROFT, AND R. L. KRAUTH-SIEGEL. 1999. Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and try-panothione reductase. Biochem Pharmacol 58: 1791-1799.
4. BRENER, Z. 1979. Present status of chemotherapy and chemoprophylaxis of human trypanosomiasis in the Western Hemisphere. Pharmacological Therapy 7: 71-90.
5. BRONDANI, D. J., C. R. NASCIMENTO, D. R. DE M. MOREIRA, A. C. LIMA LEITE, I. A. DE SOUZA, AND L. W. BIEBER. 2007. Synthesis and antitumour activity of the Primin (2-methoxy-6-n-pentyl-1,4-benzoquinone) and analogues. Medical Chemistry 3: 369-372.
6. CAMARGO, E. P. 1964. Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid media. Revista In-stituto Medical Tropical Sao Paulo 12: 93-100.
7. CASTRO, J. A., M. M. DE MECCA, AND L. C. BARTEL. 2006. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Human Experimental Toxicology 25: 471-479.
8. CROFT, S. L., M. P. BARRETT, AND J. A. URBINA. 2005. Chemotherapy of trypanosomiases and leishmaniasis. Trends in Parasitology 21: 508-512.
9. DE ANDRADE, A. L., F. ZICKER, R. M. DE OLIVEIRA, S. ALMEIDA SILVA, A. LUQUETTI, L. R. TRAVASSOS, I. C ALMEIDA, S. S. DE ANDRADE, J. G. DE ANDRADE, AND C. M. MARTELLI. 1996. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348: 1407-1413.
10. DIAS, J. C, A. C. SILVEIRA, AND C. J. SCHOFIELD. 2002. The impact of Chagas disease control in Latin America: A review. Memorias Instituto Oswaldo Cruz 97: 603-612.
11. DIAZ, J. H. 2007. Chagas disease in the United States: A cause for concern in Louisiana? Journal of the Louisiana State Medical Society 159: 21-23, 25-29.
12. DOCAMPO, R., AND S. N. MORENO. 1984. Free radical metabolites in the mode of action of chemotherapeutic agents and phagocytic cells on Trypanosoma cruzi. Reviews of Infectious Disease 6: 223-238.
13. GARG, N., AND V. BHATIA. 2005. Current status and future prospects for a vaccine against American trypanosomiasis. Expert Review of Vaccines 4: 867-880.
14. KESSL, J. J., P. HILL, B. B. LANGE, S. R. MESHNICK, B. MEUNIER, AND B. L. TRUMPOWER. 2004. Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae. Journal of Biological Chemistry 279: 2817-2824.
15. KIM, Y. M., C. H. LEE, H. G. KIM, AND H. S. LEE. 2004. Anthraquinones isolated from Cassia tora (Leguminosae) seed show an antifungal property against phytopathogenic fungi. Journal of Agriculture and Food Chemistry 52: 6096-6100.
16. KIRCHHOFF, L. V., AND R. D. PEARSON. 2007. The emergence of Chagas disease in the United States and Canada. Current Infectious Disease Report 9: 347-350.
17. LEIBY, D. A., M. H. FUCCI, AND R. J. STUMPF. 1999. Trypanosoma cruzi in a low- to moderate-risk blood donor population: Seroprevalence and possible congenital transmission. Transfusion 39: 310-315.
18. -, R. M. HERRON, JR., E. J. READ, B. A. LENES, AND R. J. STUMPF. 2002. Trypanosoma cruzi in Los Angeles and Miami blood donors: Impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 42: 549-555.
19. LOHRER, H., AND R. L. KRAUTH-SIEGEL. 1990. Purification and characterization of lipoamide dehydrogenase from Trypanosoma cruzi. European Journal of Biochemistry 194: 863-869.
20. MARTIN, D., AND R. TARLETON. 2004. Generation, specificity, and function of CD8+ T cells in Trypanosoma cruzi infection. Immunology Reviews 201: 304-317.
21. MATHER, M. W., E. DARROUZET, M. VALKOVA- VALCHANOVA, J. W. COOLEY, M. T. MCINTOSH, F. DALDAL, AND A. B. VAIDYA. 2005. Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. Journal of Biological Chemistry 280: 27458-27465.
22. MINOPRIO, P. 2001. Parasite polyclonal activators: New targets for vaccination approaches? International Journal for Parasitology 31: 588-591.
23. MONTOYA, J., A. VARELA-RAMIREZ, M. SHANMUGASUNDRAM, L. E. MARTINEZ, T. P. PRIMM, AND R. J. AGUILERA. 2005. Tandem screening of toxic compounds on GFP-labeled bacteria and cancer cells in microtiter plates. Biochemical and Biophysical Research Communications 335: 367-372.
24. MURTA, S. M., AND A. J. ROMANHA. 1998. In vivo selection of a population of Trypanosoma cruzi and clones resistant to benznidazole. Parasitology 116(Pt. 2): 165-171.
25. O'BRIEN, P. J. 1991. Molecular mechanisms of quinone cytotoxicity. Chemical and Biological Interactions 80: 1-41.
26. RAKOTOMANGA, M., M. SAINT-PIERRE- CHAZALET, AND P. M. LOISEAU. 2005. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrobial Agents and Chemotherapy 49: 2677-2686.
27. REED, L. J., F. R. LEACH, AND M. KOIKE. 1958. Studies on a lipoic acid-activating system. Journal of Biological Chemistry 232: 123-142.
28. SALMON-CHEMIN, L., E. BUISINE, V. YARDLEY, S. KOHLER, M. A. DEBREU, V. LANDRY, C. SERGHERAERT, S. L. CROFT, R. L. KRAUTH- SIEGEL, AND E. DAVIOUD-CHARVET. 2001. 2- and 3-Substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothi-one reductase and lipoamide dehydrogenase from Trypanosoma cruzi: Synthesis and correlation between redox cycling activities and in vitro cytotoxicity. Journal of Medical Chemistry 44: 548-565.
29. SCHONECK, R., O. BILLAUT-MULOT, P. NUMRICH, M. A. OUAISSI, AND R. L. KRAUTH-SIEGEL. 1997. Cloning, sequencing and functional expression of dihydrolipoamide dehydrogenase from the human pathogen Trypanosoma cruzi. European Journal of Biochemistry 243: 739-747.
30. SHANMUGASUNDARAMA, M., I. GARCIA-MARTINEZ, Q. LI, A. ESTRADA, N. E. MARTINEZ, AND L. E. MARTINEZ. 2005. Microwave-assisted solid-phase Dötz benzannulation reactions: A facile synthesis of 2,3-disubstituted-1,4 naphthoquinones. Tetrahedron Letters 46: 7545-7548.
31. TASDEMIR, D., R. BRUN, V. YARDLEY, S. G. FRANZBLAU, AND P. RUEDI. 2006. Antituberculotic and antiprotozoal activities of primin, a natural benzoquinone: In vitro and in vivo studies. Chemical Biodiversity 3: 1230-1237.
32. UI, H., A. ISHIYAMA, H. SEKIGUCHI, M. NAMATAME, A. NISHIHARA, Y. TAKAHASHI, K. SHIOMI, K. OTOGURO, AND S. OMURA. 2007. Selective and potent in vitro antimalarial activities found in four micro-bial metabolites. Journal of Antibiotics (Tokyo) 60: 220-222.
33. URBINA, J. A., AND R. DOCAMPO. 2003. Specific chemotherapy of Cha-gas disease: Controversies and advances. Trends in Parasitology 19: 495-501.
34. VERMA, R. P. 2006. Anti-cancer activities of 1,4-naphthoquinones: A QSAR study. Anticancer Agents and Medical Chemistry 6: 489-499.
35. WU, H. Q., Z. S. HUANG, X. Z. BU, Y. D. SHEN, Z. L. ZHANG, B. F. XIE, Z. C. LIU, L. Q. GU, AND A. S. CHAN. 2005. The molecular mechanisms involved in the cytotoxicity of alkannin derivatives. European Journal of Medical Chemistry 40: 1341-1345.
36. YOUNG, C., P. LOSIKOFF, A. CHAWLA, L. GLASSER, AND E. FORMAN. 2007. Transfusion-acquired Trypanosoma cruzi infection. Transfusion 47: 540-544.